{"name":"Vertex Pharmaceuticals Inc.","slug":"vertex","ticker":"VRTX","exchange":"NASDAQ","domain":"vrtx.com","description":"Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.","hq":"Boston, MA","founded":0,"employees":"6400","ceo":"Reshma Kewalramani","sector":"Biotech","stockPrice":439.17,"stockChange":7.31,"stockChangePercent":1.69,"marketCap":"$111.7B","metrics":{"revenue":11100000000,"revenueGrowth":9.5,"grossMargin":53.7,"rdSpend":3051100000,"netIncome":3953200000,"cash":6608099840,"dividendYield":0,"peRatio":28.6,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Trikafta (Copackaged)","genericName":"ELEXACAFTOR","slug":"elexacaftor","revenue":11100000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2018-01-01","label":"Symdeko (Copackaged) first approved","drug":"Symdeko (Copackaged)","drugSlug":"tezacaftor","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Trikafta (Copackaged) first approved","drug":"Trikafta (Copackaged)","drugSlug":"elexacaftor","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Journavx first approved","drug":"Journavx","drugSlug":"suzetrigine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-30","label":"SYMDEKO (COPACKAGED) Phase 3 readout (Cystic Fibrosis)","drug":"SYMDEKO (COPACKAGED)","drugSlug":"ivacaftor-tezacaftor","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Kalydeco patent cliff ($1.5B at risk)","drug":"Kalydeco","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Orkambi patent cliff ($2.5B at risk)","drug":"Orkambi","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":11100000000,"percentOfTotal":100,"drugCount":31,"colorKey":"oncology","drugs":[{"name":"Trikafta (Copackaged)","genericName":"ELEXACAFTOR","slug":"elexacaftor","indication":"Cystic fibrosis","status":"marketed","revenue":11100000000},{"name":"14C-VX-993","genericName":"14C-VX-993","slug":"14c-vx-993","indication":"Other","status":"phase_1"},{"name":"Alyftrek","genericName":"VANZACAFTOR","slug":"vanzacaftor","indication":"cystic fibrosis","status":"marketed"},{"name":"IVA","genericName":"IVA","slug":"iva","indication":"Cystic fibrosis in patients aged 6 months and older with specific CFTR mutations (gating mutations including G551D)","status":"marketed"},{"name":"LUM","genericName":"LUM","slug":"lum","indication":"Short bowel syndrome (SBS)","status":"marketed"},{"name":"Symdeko (Copackaged)","genericName":"TEZACAFTOR","slug":"tezacaftor","indication":"Cystic Fibrosis Treatment","status":"marketed"},{"name":"TEZ/IVA","genericName":"TEZ/IVA","slug":"tez-iva","indication":"Cystic fibrosis in patients with one or two F508del mutations","status":"phase_3"},{"name":"VX-828","genericName":"VX-828","slug":"vx-828","indication":"Other","status":"phase_1"},{"name":"VX-880","genericName":"VX-880","slug":"vx-880","indication":"Treatment of advanced retinitis pigmentosa","status":"phase_3"},{"name":"AVN-944 capsules for oral administration","genericName":"AVN-944 capsules for oral administration","slug":"avn-944-capsules-for-oral-administration","indication":"Other","status":"phase_1"},{"name":"Cethrin","genericName":"Cethrin","slug":"cethrin","indication":"Other","status":"phase_1"},{"name":"ELX/TEZ/IVA","genericName":"ELX/TEZ/IVA","slug":"elx-tez-iva","indication":"Cystic fibrosis in patients aged 6 years and older with at least one F508del-CFTR mutation","status":"phase_3"},{"name":"Immunosuppressant Regimen","genericName":"Immunosuppressant Regimen","slug":"immunosuppressant-regimen","indication":"Other","status":"marketed"},{"name":"Ivacaftor Exposed","genericName":"Ivacaftor Exposed","slug":"ivacaftor-exposed","indication":"Cystic fibrosis","status":"phase_2"},{"name":"LUM/IVA","genericName":"LUM/IVA","slug":"lum-iva","indication":"Cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del-CFTR mutation or heterozygous for the F508del-CFTR mutation and one residual function mutation","status":"marketed"},{"name":"Placebo (matched to HB/APAP)","genericName":"Placebo (matched to HB/APAP)","slug":"placebo-matched-to-hb-apap","indication":"Control arm in Phase 3 clinical trial (indication under investigation for HB/APAP comparator)","status":"phase_3"},{"name":"Placebo (matched to IVA)","genericName":"Placebo (matched to IVA)","slug":"placebo-matched-to-iva","indication":"Control comparator in phase 3 clinical trial for IVA (specific indication unknown)","status":"phase_3"},{"name":"Placebo (matched to SUZ)","genericName":"Placebo (matched to SUZ)","slug":"placebo-matched-to-suz","indication":"Other","status":"phase_3"},{"name":"Placebo (matched to ivacaftor)","genericName":"Placebo (matched to ivacaftor)","slug":"placebo-matched-to-ivacaftor","indication":"Matched to ivacaftor in clinical trials","status":"phase_3"},{"name":"Placebo matched to VX-661/ ivacaftor","genericName":"Placebo matched to VX-661/ ivacaftor","slug":"placebo-matched-to-vx-661-ivacaftor","indication":"Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulators","status":"phase_3"},{"name":"SUZ","genericName":"SUZ","slug":"suz","indication":"Cystic fibrosis in patients with specific CFTR mutations responsive to potentiation","status":"marketed"},{"name":"SYMDEKO (COPACKAGED)","genericName":"IVACAFTOR, TEZACAFTOR","slug":"ivacaftor-tezacaftor","indication":"Other","status":"marketed"},{"name":"TEZ","genericName":"TEZ","slug":"tez","indication":"Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation (in combination with ivacaftor)","status":"marketed"},{"name":"Tezacaftor/Ivacaftor","genericName":"Tezacaftor/Ivacaftor","slug":"tezacaftor-ivacaftor","indication":"Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation","status":"phase_3"},{"name":"VNZ/TEZ/D-IVA","genericName":"VNZ/TEZ/D-IVA","slug":"vnz-tez-d-iva","indication":"Cystic fibrosis","status":"phase_3"},{"name":"VX-121/TEZ/D-IVA","genericName":"VX-121/TEZ/D-IVA","slug":"vx-121-tez-d-iva","indication":"Cystic fibrosis in patients with one or two Phe508del alleles","status":"phase_3"},{"name":"VX-445/TEZ/IVA","genericName":"VX-445/TEZ/IVA","slug":"vx-445-tez-iva","indication":"Cystic fibrosis","status":"phase_3"},{"name":"VX-661 plus ivacaftor combination","genericName":"VX-661 plus ivacaftor combination","slug":"vx-661-plus-ivacaftor-combination","indication":"Cystic fibrosis in patients with one or two copies of the F508del mutation","status":"phase_3"},{"name":"VX-661/Ivacaftor","genericName":"VX-661/Ivacaftor","slug":"vx-661-ivacaftor","indication":"Cystic fibrosis","status":"phase_3"},{"name":"VX-770","genericName":"VX-770","slug":"vx-770","indication":"Cystic fibrosis with G551D-CFTR mutation","status":"phase_3"},{"name":"VX-809","genericName":"VX-809","slug":"vx-809","indication":"Cystic fibrosis","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"CTX001","genericName":"CTX001","slug":"ctx001","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"Pegylated Interferon Alfa 2a","genericName":"Pegylated Interferon Alfa 2a","slug":"pegylated-interferon-alfa-2a","indication":"Chronic hepatitis C","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Journavx","genericName":"SUZETRIGINE","slug":"suzetrigine","indication":"moderate to severe acute pain","status":"marketed"},{"name":"Suzetrigine (SUZ)","genericName":"Suzetrigine (SUZ)","slug":"suzetrigine-suz","indication":"Acute pain (post-operative pain)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ribavirin (Copegus®)","genericName":"Ribavirin (Copegus®)","slug":"ribavirin-copegus","indication":"Chronic hepatitis C virus (HCV) infection in combination with peginterferon alfa or direct-acting antivirals","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Exa-cel","genericName":"Exa-cel","slug":"exa-cel","indication":"Sickle cell disease","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"HB/APAP","genericName":"HB/APAP","slug":"hb-apap","indication":"Chronic hepatitis B infection","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Kalydeco","genericName":"IVACAFTOR","slug":"ivacaftor","indication":"Cystic fibrosis of the lung","status":"marketed"}]}],"pipeline":[{"name":"Trikafta (Copackaged)","genericName":"ELEXACAFTOR","slug":"elexacaftor","phase":"marketed","mechanism":"Trikafta works by correcting the faulty protein that causes cystic fibrosis, allowing the body to produce normal amounts of mucus.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"14C-VX-993","genericName":"14C-VX-993","slug":"14c-vx-993","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alyftrek","genericName":"VANZACAFTOR","slug":"vanzacaftor","phase":"marketed","mechanism":"Alyftrek potentiates the CFTR protein to facilitate chloride ion flow into cells.","indications":["cystic fibrosis","cystic fibrosis"],"catalyst":""},{"name":"IVA","genericName":"IVA","slug":"iva","phase":"marketed","mechanism":"IVA is a CFTR potentiator that increases the open probability of the cystic fibrosis transmembrane conductance regulator protein to enhance chloride ion transport.","indications":["Cystic fibrosis in patients aged 6 months and older with specific CFTR mutations (gating mutations including G551D)","Cystic fibrosis in combination with lumacaftor in patients with F508del-CFTR mutations"],"catalyst":""},{"name":"LUM","genericName":"LUM","slug":"lum","phase":"marketed","mechanism":"LUM001 is a β-catenin modulator that enhances Wnt/β-catenin signaling to promote the expansion and function of intestinal stem cells and barrier function.","indications":["Short bowel syndrome (SBS)"],"catalyst":""},{"name":"Ribavirin (Copegus®)","genericName":"Ribavirin (Copegus®)","slug":"ribavirin-copegus","phase":"marketed","mechanism":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.","indications":["Chronic hepatitis C virus (HCV) infection in combination with peginterferon alfa or direct-acting antivirals","Severe respiratory syncytial virus (RSV) infection in immunocompromised patients"],"catalyst":""},{"name":"Symdeko (Copackaged)","genericName":"TEZACAFTOR","slug":"tezacaftor","phase":"marketed","mechanism":"Tezacaftor and ivacaftor work together to increase the amount and function of CFTR protein at the cell surface, enhancing chloride transport.","indications":["Cystic Fibrosis Treatment"],"catalyst":""},{"name":"TEZ/IVA","genericName":"TEZ/IVA","slug":"tez-iva","phase":"phase_3","mechanism":"TEZ/IVA is a combination of tezacaftor and ivacaftor, which work together to increase the function of the CFTR protein in the lungs.","indications":["Cystic fibrosis in patients with one or two F508del mutations"],"catalyst":""},{"name":"VX-828","genericName":"VX-828","slug":"vx-828","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VX-880","genericName":"VX-880","slug":"vx-880","phase":"phase_3","mechanism":"VX-880 is a stem cell therapy that aims to restore vision in patients with advanced retinitis pigmentosa.","indications":["Treatment of advanced retinitis pigmentosa"],"catalyst":""},{"name":"AVN-944 capsules for oral administration","genericName":"AVN-944 capsules for oral administration","slug":"avn-944-capsules-for-oral-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CTX001","genericName":"CTX001","slug":"ctx001","phase":"phase_3","mechanism":"CTX001 is a genetically modified T-cell therapy that enhances patient immune cells to recognize and destroy cancer cells expressing specific antigens.","indications":["Relapsed or refractory multiple myeloma","Relapsed or refractory acute lymphoblastic leukemia (ALL)"],"catalyst":""},{"name":"Cethrin","genericName":"Cethrin","slug":"cethrin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ELX/TEZ/IVA","genericName":"ELX/TEZ/IVA","slug":"elx-tez-iva","phase":"phase_3","mechanism":"ELX/TEZ/IVA is a triple combination of CFTR modulators that work together to restore function of the cystic fibrosis transmembrane conductance regulator protein.","indications":["Cystic fibrosis in patients aged 6 years and older with at least one F508del-CFTR mutation","Cystic fibrosis in patients with other CFTR mutations responsive to CFTR modulation"],"catalyst":""},{"name":"Exa-cel","genericName":"Exa-cel","slug":"exa-cel","phase":"phase_3","mechanism":"Exa-cel is an in vivo CRISPR gene-editing therapy that modifies the BCL11A gene to reactivate fetal hemoglobin production in patients with sickle cell disease or beta-thalassemia.","indications":["Sickle cell disease","Beta-thalassemia major"],"catalyst":""},{"name":"HB/APAP","genericName":"HB/APAP","slug":"hb-apap","phase":"phase_3","mechanism":"HB/APAP is a combination therapy that pairs a hepatitis B antigen with acetaminophen to modulate immune responses against hepatitis B infection.","indications":["Chronic hepatitis B infection"],"catalyst":""},{"name":"Immunosuppressant Regimen","genericName":"Immunosuppressant Regimen","slug":"immunosuppressant-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ivacaftor Exposed","genericName":"Ivacaftor Exposed","slug":"ivacaftor-exposed","phase":"phase_2","mechanism":"Potentiates CFTR chloride channel function","indications":["Cystic fibrosis"],"catalyst":""},{"name":"Journavx","genericName":"SUZETRIGINE","slug":"suzetrigine","phase":"marketed","mechanism":"Journavx blocks sodium channels in the nervous system to reduce pain signal transmission.","indications":["moderate to severe acute pain","postoperative pain"],"catalyst":""},{"name":"Kalydeco","genericName":"IVACAFTOR","slug":"ivacaftor","phase":"marketed","mechanism":"Kalydeco works by helping the defective protein in cystic fibrosis cells function more normally.","indications":["Cystic fibrosis of the lung"],"catalyst":""},{"name":"LUM/IVA","genericName":"LUM/IVA","slug":"lum-iva","phase":"marketed","mechanism":"LUM/IVA is a combination of lumacaftor (a CFTR corrector) and ivacaftor (a CFTR potentiator) that work together to improve the processing and function of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein.","indications":["Cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del-CFTR mutation or heterozygous for the F508del-CFTR mutation and one residual function mutation"],"catalyst":""},{"name":"Pegylated Interferon Alfa 2a","genericName":"Pegylated Interferon Alfa 2a","slug":"pegylated-interferon-alfa-2a","phase":"marketed","mechanism":"Pegylated Interferon Alfa 2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.","indications":["Chronic hepatitis C","Chronic hepatitis B","Certain malignancies (e.g., melanoma, follicular lymphoma)"],"catalyst":""},{"name":"Placebo (matched to HB/APAP)","genericName":"Placebo (matched to HB/APAP)","slug":"placebo-matched-to-hb-apap","phase":"phase_3","mechanism":"A placebo control matched to the active comparator HB/APAP (hydrocodone bitartrate/acetaminophen) that contains no pharmacologically active ingredients.","indications":["Control arm in Phase 3 clinical trial (indication under investigation for HB/APAP comparator)"],"catalyst":""},{"name":"Placebo (matched to IVA)","genericName":"Placebo (matched to IVA)","slug":"placebo-matched-to-iva","phase":"phase_3","mechanism":"Placebo is an inert control substance with no active pharmacological mechanism.","indications":["Control comparator in phase 3 clinical trial for IVA (specific indication unknown)"],"catalyst":""},{"name":"Placebo (matched to SUZ)","genericName":"Placebo (matched to SUZ)","slug":"placebo-matched-to-suz","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo (matched to ivacaftor)","genericName":"Placebo (matched to ivacaftor)","slug":"placebo-matched-to-ivacaftor","phase":"phase_3","mechanism":"This drug has no therapeutic effect.","indications":["Matched to ivacaftor in clinical trials"],"catalyst":""},{"name":"Placebo matched to VX-661/ ivacaftor","genericName":"Placebo matched to VX-661/ ivacaftor","slug":"placebo-matched-to-vx-661-ivacaftor","phase":"phase_3","mechanism":"This is a placebo control arm in a clinical trial comparing VX-661 (a CFTR corrector) combined with ivacaftor (a CFTR potentiator) against placebo in cystic fibrosis patients.","indications":["Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulators"],"catalyst":""},{"name":"SUZ","genericName":"SUZ","slug":"suz","phase":"marketed","mechanism":"SUZ is a CFTR potentiator that enhances the function of cystic fibrosis transmembrane conductance regulator protein to improve chloride transport in cystic fibrosis patients.","indications":["Cystic fibrosis in patients with specific CFTR mutations responsive to potentiation"],"catalyst":""},{"name":"SYMDEKO (COPACKAGED)","genericName":"IVACAFTOR, TEZACAFTOR","slug":"ivacaftor-tezacaftor","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Suzetrigine (SUZ)","genericName":"Suzetrigine (SUZ)","slug":"suzetrigine-suz","phase":"marketed","mechanism":"Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.","indications":["Acute pain (post-operative pain)"],"catalyst":""},{"name":"TEZ","genericName":"TEZ","slug":"tez","phase":"marketed","mechanism":"TEZ (tezacaftor) is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly and traffic to the cell surface.","indications":["Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation (in combination with ivacaftor)","Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulation"],"catalyst":""},{"name":"Tezacaftor/Ivacaftor","genericName":"Tezacaftor/Ivacaftor","slug":"tezacaftor-ivacaftor","phase":"phase_3","mechanism":"Tezacaftor is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly, while ivacaftor is a CFTR potentiator that increases the channel-opening probability of CFTR at the cell surface.","indications":["Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation","Cystic fibrosis in patients with other CFTR mutations responsive to CFTR modulation"],"catalyst":""},{"name":"VNZ/TEZ/D-IVA","genericName":"VNZ/TEZ/D-IVA","slug":"vnz-tez-d-iva","phase":"phase_3","mechanism":"VNZ/TEZ/D-IVA is a triple combination therapy consisting of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a corrector, and a potentiator.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"VX-121/TEZ/D-IVA","genericName":"VX-121/TEZ/D-IVA","slug":"vx-121-tez-d-iva","phase":"phase_3","mechanism":"VX-121/TEZ/D-IVA is a triple combination of a cystic fibrosis transmembrane conductance regulator (CFTR) corrector (VX-121), a CFTR potentiator (tezacaftor), and a CFTR amplifier (ivacaftor).","indications":["Cystic fibrosis in patients with one or two Phe508del alleles","Cystic fibrosis in patients with one F508del allele and one minimal function mutation"],"catalyst":""},{"name":"VX-445/TEZ/IVA","genericName":"VX-445/TEZ/IVA","slug":"vx-445-tez-iva","phase":"phase_3","mechanism":"VX-445/TEZ/IVA is a combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"VX-661 plus ivacaftor combination","genericName":"VX-661 plus ivacaftor combination","slug":"vx-661-plus-ivacaftor-combination","phase":"phase_3","mechanism":"VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and ivacaftor is a CFTR potentiator.","indications":["Cystic fibrosis in patients with one or two copies of the F508del mutation"],"catalyst":""},{"name":"VX-661/Ivacaftor","genericName":"VX-661/Ivacaftor","slug":"vx-661-ivacaftor","phase":"phase_3","mechanism":"VX-661/Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"VX-770","genericName":"VX-770","slug":"vx-770","phase":"phase_3","mechanism":"VX-770 is a CFTR potentiator that increases the opening probability and duration of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel at the cell surface.","indications":["Cystic fibrosis with G551D-CFTR mutation","Cystic fibrosis with other gating mutations"],"catalyst":""},{"name":"VX-809","genericName":"VX-809","slug":"vx-809","phase":"phase_3","mechanism":"VX-809 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector.","indications":["Cystic fibrosis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"VRTX Reports Fourth-Quarter and Full-Year 2023 Financial Results","summary":"Vertex Pharmaceuticals Inc. (VRTX) reported its fourth-quarter and full-year 2023 financial results, with revenue of $2.4 billion and a net income of $1.3 billion.","drugName":"","sentiment":"positive"},{"date":"2023-10-27","type":"deal","headline":"Vertex Pharmaceuticals and CRISPR Therapeutics Announce Collaboration to Develop Gene Editing Therapies","summary":"Vertex Pharmaceuticals Inc. (VRTX) and CRISPR Therapeutics AG (CRSP) announced a collaboration to develop gene editing therapies for cystic fibrosis and other diseases.","drugName":"","sentiment":"positive"},{"date":"2023-06-09","type":"regulatory","headline":"FDA Approves Trikafta for Cystic Fibrosis Patients with Certain Mutations","summary":"The U.S. Food and Drug Administration (FDA) approved Trikafta (elexacaftor/tezacaftor/ivacaftor) for the treatment of cystic fibrosis patients with certain mutations.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5wWHU3c2hTVEdDRC1XcGtTUXpvUElCX0tMVHBaWXViRjBwTDYxSDRnNHM2Tnpod2hGN2Rza3NZcmJET2lPSVF0QnJoblRZSDIwRG1KNEtQMzZVcUN5UFpiYkhXWkdfTnpLMGJDUUxmZWRBUG05OFVOQXFlRllqZmc?oc=5","date":"2026-04-07","type":"pipeline","source":"Seeking Alpha","summary":"Vertex Pharma in pact with Halozyme for Hypercon (VRTX:NASDAQ) - Seeking Alpha","headline":"Vertex Pharma in pact with Halozyme for Hypercon (VRTX:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOa09Zdm1QQnNVWVN3aXpCNEU4T3FRZmpmamxjTXUydWYyOVUxQXRld0tsdTRXcmZJY05qcTV6a0tjS0pPM0N4RXU1ZVlYbHYxSm0wNDVQeE16TV9iZXdBNF9US2pxc1dqOHdwUHBfZEdTcFgtWm1COGc1aFpmdHQ5ZEszUHpaMThUQWI3Y3RzdllsMXdCX2c?oc=5","date":"2026-04-01","type":"regulatory","source":"Seeking Alpha","summary":"Vertex Pharma wins FDA label expansion for cystic fibrosis therapies - Seeking Alpha","headline":"Vertex Pharma wins FDA label expansion for cystic fibrosis therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPbE5PVy05b181bkFYZ29vV1JmVXUyMjNVRUFKZm5RRVBKcWk2SXBPWEIzVy1uZWd2RjhfbEg5OXdUajhZLXJGMUxhVFlhN3h6VUdWbGtNN1k0Z3JzYmxnZzBTbFRXdWxDU2MwLXpaM3IyMWlyelJQSE9KRGNtZnJUd3lVT0VIRUlKWDhCMk5mUVBpMkJ1TkpIS0lrdGhuR3VBOVNnR2hLa0xfRFYzN3VndkltcXhRQ2l6a3Q3cW1TOHI2UQ?oc=5","date":"2026-03-31","type":"pipeline","source":"GuruFocus","summary":"Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus","headline":"Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX)","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNQkNWRVV0QXRDX3lRNTdXekFUUms0YzJ3ZjcxM3BvY1VHUG9YQWM0dGZUS0tFeGhwS1dQbU03aVM1dlpPOW4xcjNiQXg0SllpTFpkZk5RVlpaeDZsbGhnV0dVbk9BTHd4X0JncGdjWWQwNk5Fa0dEck5feWxiNzhwUWlNSUdtYnRwc0lGc29ILXloUkRwN01GTUhoeVJxalRVVHJyNnBsc3RBR0lpT0wtdk1wZVhVS0hCd1djUEJVWS1vZUI5SVRKTjhnQmJfQTEzUWN3UGRBT0h0WG5FZDRB?oc=5","date":"2026-03-20","type":"pipeline","source":"MarketBeat","summary":"CIBC Bancorp USA Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat","headline":"CIBC Bancorp USA Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPMElNdHM1Qm5kMzV6dGxFWWUxdVZzQlNtckpGREZZbnFCRzJ3TFpfWDg3enZDSFF5cncycTNCQ3Q0WFh1eEVCQV9tbWVrRG1FWWxSRmJhNzdlbTdFZE9QWllNSUYyMHpGeUZZV1psS3c4X0hLUGdsMVR2bWI2cmtHZ2VQTDF5UGJibHcwdlV3MmZNbjgxb3MwdVBzZ0Y4R3h1LUNUR0s5MWpVQ3F2NmN0OWZsOElvVjBNVy1FczZDZ2NLUQ?oc=5","date":"2026-03-17","type":"pipeline","source":"GuruFocus","summary":"Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus","headline":"Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOeEZ5RnJsTm1oUjJyN2d6SHFuQ1p0V3Zwc1RyOEp1VTJ5ZlVkVDFSekZmSEZKeEFOMUN0eDQzdXN2Y3lFNGpYOU84Wm85ZkRIeWVXMjVXcVdzLVBESWxvRW1RUFU2aTZ0cmtmc3RSc0p3V01DTjhZcHhseXlkYUQydjBPX0xYZVQ5RTZ3ZnVYQ1Y2MEVXX0xrbFFINWlZRGRjN2FKbE0xUmx4blg1RnlGTVoxT1pyVkFCVE5Oc3FDRUtINXJIUFdiM1l2ZHVMUm44UGc?oc=5","date":"2026-03-10","type":"regulatory","source":"Investopedia","summary":"This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results - Investopedia","headline":"This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxORUg5bnNNZ19qY19RM3lDRndQQlNYelRiMWRfdUsycnpjUHhNcXI1OWVpTUNfMnlNVGxkUklKcWw2VVpGMFBYeWZ3RTliV3RnSnBJa3pOYzZMSmxwQkZrQW96bFE2R1hpLTBWdWpBcTdvY25mTUZqRmpkY1J5VDFXZFliakRhOVpaQVdoNTBELURGVjVjeVFGRDllb29laHBFV3BkczNYVnZqQVFkTF9mamdpeWhNQ2VrbHIzaVV5bEJlbXpnSFExaVBvRUxWVTQ?oc=5","date":"2026-03-10","type":"pipeline","source":"MarketBeat","summary":"Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley - MarketBeat","headline":"Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNX2R4WC1Oc2NiVDRRVURhNGVCblU0ZnMwMWFXVzdnVHo1UkdFWlZsQlgzamhSVHMtMTFMYWlYR0hqdXBhbWN2MlNRa1lYeldLSkZpdkI0SEc0TkZnd0VncVN6UExHR2FPVUJvOVBxeExOTG5qRnN0MnlfUS00UEJybGZ3emxhZw?oc=5","date":"2026-02-13","type":"pipeline","source":"Yahoo Finance","summary":"Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays - Yahoo Finance","headline":"Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdnJCQUh2RjJnRGNNdzlfNDVTSlZXSGthVWU2V2JFdkRRUXF6Y0M0aUh0aWU3NENFZXNONC1NTFJzZ3NtV2x1R3VtV25VaDJoWDN1VG56S1FvZTNNX2JFM0I0UGVPRXFoT1pEYWUwc1dUTGRUMXZuMWVlNlNxYl9xWGtIcEZyX2tNaHl2OVFJOUhPUS1iWlhCM0IzZlZGTTRWZ0xWblk3aVpFZGc?oc=5","date":"2026-01-31","type":"pipeline","source":"Finviz","summary":"Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story - Finviz","headline":"Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPNVNoeE5OWnBnUUtqbHZhMVVEWVdRYm1hazQzZzB3N0tsSVA4R1pxVkRIalZtT3JBQWVfWVFTVld6S2ZjWDB0RjVQZ3FDdnBDQkdoOGFvVk90RXRRekhMVW5JeHpmVFRQRnJzS28ydzJLX2VwMTlOblJEM3lzQnpaaXpKTS1LSE9CdnVyRV9JU1I3OXNTVEF2bzRhWVRPYV9UcG44cFozY3lCUFF3NFVZZ2pWXy1fZWsxSkxETGQzVjZ5MmI1OEltVFNEM1VETEpRQUd1ZnBPRlo1cTBC?oc=5","date":"2026-01-20","type":"earnings","source":"Business Wire","summary":"Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th - Business Wire","headline":"Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNQk5YYjBqM0ZiUmRKRnZNeTdDeDk5M1hBZjZ1UkVyYzc2N1JhQjJxNG5XclVVQUozQjlFLThRMDJiTEhBWXRCS3VtelYxZjlwTzdqZXF4LVZtODhKYUszVENaTDQxaE9Yb0lYMzFwdkgtNWpPamMxY1BBRDRaTW9LOFhpZVYtbGJXUzFrRmJiaw?oc=5","date":"2026-01-06","type":"pipeline","source":"Finviz","summary":"Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why - Finviz","headline":"Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQV1g2UTlYQ2VFVUQybnItNDVkZTdTQ08xdlZTZjVrN2hhZkIxckEwcFd0dTQzWUxzMFdjT2tXVjdoQXhZcDczMmpiZ3B3NXptRmpLVmw5TUtMbG5XYU9SdFVkR0ZlTWZMcUs2NVphNGVQeDU4a3FiZFFnWVBqaDN0Q0M4dWZxbWVEMzFhR20tY21TZw?oc=5","date":"2025-08-20","type":"pipeline","source":"The Motley Fool","summary":"What's Wrong With Vertex Pharmaceuticals Stock? - The Motley Fool","headline":"What's Wrong With Vertex Pharmaceuticals Stock?","sentiment":"neutral"}],"patents":[{"drugName":"Kalydeco","drugSlug":"ivacaftor","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Orkambi","drugSlug":"lumacaftor/ivacaftor","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":2500000000}],"drugCount":39,"phaseCounts":{"marketed":15,"phase_1":4,"phase_3":19,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences Inc. (GILD)","Cystic Fibrosis Foundation Therapeutics Inc. (CFFT)","Pulmatrix Inc. (PULM)"],"therapeuticFocus":["Cystic Fibrosis","Respiratory Diseases"],"financials":{"source":"sec_edgar","revenue":2488652000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":2488652000,"period":"2017-12-31"},{"value":651634000,"period":"2017-12-31"},{"value":578165000,"period":"2017-09-30"},{"value":544135000,"period":"2017-06-30"},{"value":714718000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":3051100000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":3953200000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":25643000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":439.17,"previousClose":431.86,"fiftyTwoWeekHigh":510.77,"fiftyTwoWeekLow":362.5,"fiftyTwoWeekRange":"362.5 - 510.77","fiftyDayAverage":467.23,"twoHundredDayAverage":438.28,"beta":0.37,"enterpriseValue":105135104000,"forwardPE":20,"priceToBook":5.98,"priceToSales":9.31,"enterpriseToRevenue":8.76,"enterpriseToEbitda":21.61,"pegRatio":2.12,"ebitda":4865999872,"ebitdaMargin":40.5,"freeCashflow":2573112576,"operatingCashflow":3631399936,"totalDebt":2036000000,"debtToEquity":10.9,"currentRatio":2.9,"returnOnAssets":12.2,"returnOnEquity":22.5,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":29,"targetMeanPrice":547.79,"targetHighPrice":641,"targetLowPrice":330,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.2,"institutionHeldPercent":97.6,"sharesOutstanding":254359735,"floatShares":253244144,"sharesShort":4127429,"shortRatio":2.9,"shortPercentOfFloat":1.6,"epsTrailing":15.33,"epsForward":21.91,"revenuePerShare":46.94,"bookValue":73.49,"officers":[{"age":69,"name":"Dr. Jeffrey Marc Leiden M.D., Ph.D.","title":"Executive Chairman"},{"age":52,"name":"Dr. Reshma  Kewalramani FASN, M.D.","title":"CEO, President & Director"},{"age":57,"name":"Mr. Charles F. Wagner Jr.","title":"Executive VP, COO & CFO"},{"age":60,"name":"Dr. David M. Altshuler M.D., Ph.D.","title":"Executive Officer"},{"age":55,"name":"Dr. Ourania  Tatsis Ph.D.","title":"Executive VP and Chief Regulatory & Quality Officer"},{"age":48,"name":"Ms. Kristen C. Ambrose CPA","title":"Senior VP & Chief Accounting Officer"},{"age":56,"name":"Dr. Mark  Bunnage D.Phil","title":"Executive VP & Chief Scientific Officer"},{"age":null,"name":"Ms. Susie  Lisa C.F.A.","title":"Senior Vice President of Investor Relations"}],"industry":"Biotechnology","irWebsite":"http://www.vrtx.com/finances.html","website":"https://www.vrtx.com","phone":"617 341 6100"}}